<!DOCTYPE html>
<html>

  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width initial-scale=1" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <title>RNA Interference - Field Recap</title>
    <meta name="description" content="Personal Website and Blog
">

    <link rel="stylesheet" href="/css/main.css">
    <link rel="canonical" href="https://www.martinholub.com/2024/10/16/RNAi.html">

    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.7.2/css/all.min.css">
	<link rel="stylesheet" href="/css/academicons.css"/>
    <link href="/css/lightbox.css" rel="stylesheet">

    <link rel="stylesheet" href="/css/zenburn.css"/>

    <!-- collect tags -->
    
      <!-- collect tags from blog posts -->
<!-- source: https://longqian.me/2017/02/09/github-jekyll-tag/ --->







    

	<link type="application/atom+xml" rel="alternate" href="https://www.martinholub.com/feed.xml" title="Martin Holub Blog" />
</head>

  
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-1ZBQKKLMRB"></script>
  <script>
	window.dataLayer = window.dataLayer || [];
	function gtag(){dataLayer.push(arguments);}
	gtag('js', new Date());

	gtag('config', 'G-1ZBQKKLMRB');
  </script>

  <script type="text/javascript"
    src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML">
	</script>

  <body>

    <header class="site-header">

  <div class="wrapper">

    <nav class="site-nav">

      <div class="trigger">
        <!-- Martin Holub Blog instead of blog -->
        <a class="page-link" href="/">about</a>

        <!-- ( for page in site.pages )  was previously-->
        
          
          <a class="page-link" href="/blog">blog</a>
          
        
          
          <a class="page-link" href="/research">research</a>
          
        
          
          <a class="page-link" href="/projects">projects</a>
          
        
          
          <a class="page-link" href="/resources">resources</a>
          
        
          
          <a class="page-link" href="/subscribe">subscribe</a>
          
        

      </div>
    </nav>

  </div>

</header>


    <div class="page-content">
      <div class="wrapper">
        <div class="post">

  <header class="post-header">
    <h1 class="post-title">RNA Interference - Field Recap</h1>
    <p class="post-meta">October 16, 2024 — 19:22 • <a href="https://martinholub.github.io/2024/10/16/RNAi.html#disqus_thread">0 Comments</a></p>
    <span class="post-meta">[
      
        
          <a href="/tag/biotech"><code class="highligher-rouge"><nobr>biotech</nobr></code>&nbsp;</a>
      
        
          <a href="/tag/science"><code class="highligher-rouge"><nobr>science</nobr></code>&nbsp;</a>
      
    ]</span>
  </header>
  

  <article class="post-content">
    <p><i>This field recap was writen at end of Q22024. Events that took place after this date are not reflected.</i></p>

<p>In this post, I provide a brief field recap on RNA interference as therapeutic modality. First, I provide background on its biological mechanisms. Next, I follow up with an overview of the siRNA therapeutics field, highlighting approved drugs, as well major ongoing trials. I conclude with a short recap.</p>

<h2 id="mechanism-of-rna-interference">Mechanism of RNA Interference</h2>

<p>RNA interference (RNAi) is a process by which RNA molecules suppress gene expression in sequence specific fashion. The process was initially described in late 80’s and early 90’s, [<a href="https://doi.org/10.1016/0092-8674(84)90050-3">ref</a>, <a href="https://doi.org/10.1242/dev.113.2.503">ref</a>], and elucidated at the turn of the century with work that yielded the 2006 Nobel Prize in Physiology and Medicine [<a href="https://www.nature.com/articles/35888">ref</a>]. RNAi is a natural process of gene regulation that has physiological role in wide range of organisms, including mammals and plants. Despite some important differences, the process is mostly conserved among species. In the following, we describe it in broad strokes, focusing on its mechanism in eukaryotic and human cells.</p>

<p>In RNAi, double-stranded RNA (dsRNA) enters cells where it is recognized by the Dicer enzyme. Dicer contains two RNAse III domains. When recruited to dsRNA, two Dicer enzymes work in tandem to cleave the molecule at a regular interval of ~22 nucleotides. The cleavage generates 2 nucleotide overhangs at the 3’ end. The 5’ end, left unprotected, is rapidly phosphorylated. The resulting RNA molecule is the <strong>small interfering RNA (siRNA)</strong>, which sets off silencing. Notably, exogenously administered siRNAs are also capable of triggering silencing.</p>

<p>The siRNA molecule prompts the assembly of an effector nuclease complex <strong>RISC (RNA-induced silencing complex)</strong>, whereby the RISC complex binds the siRNA and unwinds it. The sense strand, also called passenger strand, is digested by Ago2, a member of the complex and of the Argonaut protein family. The antisense strand, also called guide strand, guides RISC complex towards a complementary mRNA sequence. Upon recognition, the mRNA sequence is cleaved and digested, effectively leading to silencing of corresponding gene. Once the RISC complex is activated, it is capable of targeting numerous mRNA transcript copies, producing an effect that is sustained over several weeks in non-dividing cells [<a href="https://www.nature.com/articles/nrd2742">ref</a>].</p>

<p>The description we gave given so far is accurate, but omits some details that are relevant to applications. <strong>First</strong>, the mRNA cleavage and digestion is only one mechanism by which siRNA produces silencing. Chromatin modification and remodeling, as well translational inhibition, have been shown to play a role, albeit to smaller extent. <strong>Second</strong>, siRNA is capable of silencing sequences other than its perfect complements. This can happen in two ways: a) by extension of the silencing signal in the 3’ -&gt; 5’ direction, effectively leading to silencing of sequences left to the target, and b) by RISC’s tolerance to mismatches, particularly at the ends of the guide sequence [<a href="https://doi.org/10.1016/j.omtn.2022.02.004">ref</a>]. <strong>Third</strong>, mammalian somatic cells exhibit nonspecific response to delivery of dsRNA, and so does the innate immune system react to it by raising interferon levels. This precludes dsRNA use from silencing applications [<a href="https://www.nature.com/articles/ncb0200_70">ref</a>]. Fortunately, the direct delivery of siRNAs is generally well tolerated. <strong>Fourth</strong>, studies in simpler organisms demonstrated the spreading of silencing signal into cell types beyond the target [<a href="https://www.science.org/doi/full/10.1126/science.1068836">ref</a>]. The extent to which this plays a role in human cells is not fully understood.</p>

<h2 id="aspects-of-therapeutic-sirna-design">Aspects of Therapeutic siRNA Design</h2>

<p>With only ~22 nucleotides (practically between 19 and 25), siRNA is a relatively simple molecule. The intense work over the past two decades demonstrated that this is by no way a limitation to sophistication of designs and modifications that it can lend itself to. In the following we describe several of the most widely adopted design features, including <strong>formulation</strong>, chemical <strong>modification</strong> of individual bases, and <strong>conjugation</strong> to additional moieties.</p>

<p>The earliest examples of siRNA’s were minimally modified, and their formulation was as much as subcutaneous injection of a solution in physiological buffer. Motivated by the need to prevent siRNAs from degradation, and to target their delivery to specific tissues, in the 2000’s the field explored different formulation methods. These included polymer nanoparticles and liposomes (or lipid nanoparticles, LNPs) [<a href="https://www.nature.com/articles/nmat3765">ref</a>]. The latter, LNPs, become part of the first siRNA therapy, approved by both the FDA and the EMA in 2018 [<a href="https://www.nature.com/articles/s41565-019-0591-y">ref</a>].</p>

<p>Finding the right formulation for LNPs was, however, a substantial undertaking [<a href="https://www.nature.com/articles/s41565-019-0591-y">ref</a>]. Consequently, the field shifted away from encapsulation formulations. Instead, the focus turned to chemically modifying siRNAs, and conjugating them to moieties that garner tissue specificity. Variants of this approach are dominant among all the approved therapies, as well as siRNA drug candidates currently in clinical trials. We illustrate this at detail on the example of givosiran [<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1807838">ref</a>].</p>

<!-- All modifications featured on this molecule are also present on both clinical assets of Silence Therapeutics \[[ref](https://patents.google.com/patent/US20190119676A1)\]. 
-->

<p>Givosiran is a siRNA therapeutic agent for reducing levels of expression of delta aminolevulinic acid synthase 1 (ALAS1). Givosiran is approved in patients with acute intermittent porphyria, with authorizations issued at the end of 2019 by the FDA, and two months later by the EMA. It is marketed under the brand name Givlaari by Alnylam Pharmaceuticals. Givosiran is a fully chemically modified siRNA (Fig.1). Apart from featuring the canonical two nucleotide 3’ overhang and 5’ phosphate, it includes a number of modifications. All RNA bases are modified at the 2’ position of a ribose: either with <strong>2’-Fluoro (2’-F)</strong>, or <strong>2’-O-Methyl (2’-OMe)</strong>. Both modifications improve target binding affinity [<a href="http://dx.doi.org/10.1038/nbt.3765">ref</a>]. The 2’-OMe modification has been further shown to foster nuclease resistance, and reduce immune stimulation [<a href="http://dx.doi.org/10.1038/nbt.3765">ref</a>]. 5’ end is modified with <strong>E-vinyl phosphonate (5’-E-VP)</strong>. 5’-E-VP is a phosphatase resistant 5’-phosphate analog, improving tissue accumulation by increasing chemical stability [<a href="https://doi.org/10.1093/nar/gkx507">ref</a>]. Number of phosphodiester bonds at the end of each strand have been replaced by phosphorothioate, increasing the molecule’s stability, as well as facilitating its trafficking and uptake [<a href="http://dx.doi.org/10.1038/nbt.3765">ref</a>]. Finally the 3’ end of the sense strand is conjugated to a trivalent GalNAc (Fig. 2). <strong>GalNAc, N-Acetyl galactosamine</strong>, is an amino-derivative of galactose and the ligand for asialoglycoprotein receptor (ASGPR), and abundant transmembrane protein in hepatocytes. The moiety is responsible for guiding the siRNA molecule to these cells, which are targets of the therapeutic.</p>

<div class="img_row"> <img class="col three" src="/img/rnai_fig1.png" alt="" title="Header" /> </div>
<div class="col three caption">Figure 1: Schematic depiction of the molecular composition of Givosiran. AS – antisense, S – sense strands. See text for detailed description.</div>

<div class="img_row"> <img class="col three" src="/img/rnai_fig2.png" alt="" title="Header" /> </div>
<div class="col three caption">Figure 2: The molecular structure of the (GalNAc)3 conjugate shown in Fig. 1.</div>

<p>Both the position and type of the modifications have effect on number of therapeutically relevant parameters including toxicity, target binding and tissue accumulation. Despite large body of research available to date, and because number of modifications other than described are possible [<a href="https://www.nature.com/articles/s41392-020-0207-x">ref</a>], the discovery of siRNA molecules for therapeutic applications continues to be heavily empirical. The best performing molecules must be found by extensive candidate screening. Due to difficulty of translating in-vitro to in-vivo results, this happens largely in animal models.</p>

<p>Similarly, so far we have discussed only one type of targeting moiety, GalNAc. Clearly, the utility of siRNA therapeutics is not limited to hepatocytes. However, targeting other cell types requires careful choice and optimization of the 3’ sense-strand conjugate, as well as its linker. Number of extrahepatic targeting ligands have been demonstrated so far. These include lipids [<a href="https://academic.oup.com/nar/article/47/3/1082/5245439">ref</a>], peptides [<a href="https://doi.org/10.1021/jacs.0c12043">ref</a>], centyrins [<a href="https://doi.org/10.1016/j.ymthe.2021.02.015">ref</a>], antibodies [<a href="https://doi.org/10.1093%2Fnar%2Fgkaa286">ref</a>], aptamers [<a href="https://doi.org/10.1016/j.omtn.2017.12.015">ref</a>], as well as branched siRNA arrangements [<a href="https://www.nature.com/articles/s41587-019-0205-0">ref</a>]. Finally, recent advances in mRNA-based therapeutics, commonly encapsulated as LNPs, have spurred new wave of interest in liposomes, particularly in advanced formulations with newly synthesized lipids [<a href="https://www.nature.com/articles/s41563-024-01867-3">ref</a>].</p>

<h2 id="overview-of-sirna-therapeutic-applications">Overview of siRNA Therapeutic Applications</h2>

<p>siRNA has become a popular therapeutic modality, and is pursued for number of targets across tens of indications by sizeable number of companies. As of Q12024, there were 6 FDA approved siRNA drugs (Table 1).</p>

<div class="img_row"> 
<img class="col three" src="/img/rnai_table1.png" alt="" title="Header" /> 
</div>
<div class="col three caption">Table 1: FDA approved siRNA therapeutics [<a href="https://www.nature.com/articles/s41587-023-02105-y/tables/1">ref</a>]. (h)ATTR– (hereditary) transthyretin-mediated amyloidosis. ‡ in phase III for a) major adverse cardiovascular events (MACE), and b) ASCVD and elevated LDL-C. 
</div>

<p>Additionally, several investigational molecules were in stage phase III trials (Table 2).</p>

<div class="img_row"> 
<img class="col three" src="/img/rnai_table2.png" alt="" title="Header" /> 
</div>
<div class="col three caption">Table 2: siRNA investigational drugs in stage phase III trials. NAION - nonarteritic anterior ischemic optic neuropathy. gMG - generalized myasthenia gravis, PNH - paroxysmal nocturnal hemoglobinuria, sHTG- severe hypertriglyceridemia, (AS)CVD – (atherosclerotic) cardiovascular disease, AATD - alpha-1 antitrypsin deficiency, ‡ - company deck [<a href="https://ir.arrowheadpharma.com/static-files/5aeef413-bfc6-4ef0-9a33-bdb8ad939483">ref</a>].
</div>

<p>Finally, there is number of candidates in phase II trials (Table 3).</p>

<div class="img_row"> 
<img class="col three" src="/img/rnai_table3.png" alt="" title="Header" /> 
</div>
<div class="col three caption">Table 3: Examples of siRNA investigational drugs in phase II trials [<a href="https://pubs.acs.org/doi/full/10.1021/acs.bioconjchem.3c00205">ref</a>, <a href="https://www.nature.com/articles/s41587-022-01334-x">ref</a>]. Con. – conjugate, CAA - cerebral amyloid angiopathy.
</div>

<h2 id="conclusions">Conclusions</h2>

<p>It is an exciting time for both developers of RNAi therapeutics as well as patients that stand to benefit from them, with number of recently approved drugs and several potential blockbusters queuing up in the pipeline. However, two aspects darken this otherwise rosy picture. <strong>I)</strong> Cardiovascular disease is by far the largest pursued indication, but, at the moment of writing, there are at least five late stage clinical assets going after it! This is great news for patients, but bad news for developers, who will see the blockbuster potential of their drugs dwindle. <strong>II)</strong> There is a very apparent lack of diversity of targeting strategies, with majority of the (investigational) drugs leveraging GalNAc conjugation for delivery to hepatocytes. Some target eye or skin. Only three clinical trials for lungs and kidneys have reached phase II, as did one trial for the brain [<a href="https://www.nature.com/articles/s12276-023-00998-y">ref</a>]. The sustained success of RNAi therapeutics will be conditioned on RNAi companies’ ability to devise strategies for extrahepatic delivery, with muscle and brain representing particularly attractive, but also elusive, targets.</p>

<p>Thanks for reading everyone! Did you enjou this recap? And what area would you like to see covered next? Let me know in the comments.</p>

  </article>

  
<!---
Call Fontawesome in the head section or in the location where you place the share bar
<link href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css" rel="stylesheet">
--->
<hr>
<br/>
<!---<center><p><script async src="https://eocampaign1.com/form/cfe45fdc-109a-11ef-a9e2-bf0899395051.js" data-form="cfe45fdc-109a-11ef-a9e2-bf0899395051"></script></p></center>--->
<div class="share-box center" style="width: 60%; margin: 0px auto;">
<h2 class="center">Share this:</h2>
<br/>
<a class="l" href="https://www.linkedin.com/shareArticle?mini=true&url=https://www.martinholub.com/2024/10/16/RNAi.html&title=RNA Interference - Field Recap&summary=&source=martinholub" onclick="window.open(this.href, 'mywin',
'left=20,top=20,width=500,height=500,toolbar=1,resizable=0'); return false;"><i class="fa-brands fa-linkedin"></i><span> linkedin</span></a>

<a class="t" href="https://twitter.com/intent/tweet?text=RNA Interference - Field Recap&url=https://www.martinholub.com/2024/10/16/RNAi.html" onclick="window.open(this.href, 'mywin',
'left=20,top=20,width=500,height=500,toolbar=1,resizable=0'); return false;"><i class="fa-brands fa-square-x-twitter"></i><span> x</span></a>

<a class="t" href="https://bsky.app/intent/post?text=RNA Interference - Field Recap&url=https://www.martinholub.com/2024/10/16/RNAi.html" onclick="window.open(this.href, 'mywin', 'left=20,top=20,width=500,height=500,toolbar=1,resizable=0'); return false;">
  <i class="fa-brands fa-square-bluesky"></i><span> bluesky</span>
</a>
<!---
<a class="g" href="https://plus.google.com/share?url=https://www.martinholub.com/2024/10/16/RNAi.html" onclick="window.open(this.href, 'mywin',
'left=20,top=20,width=500,height=500,toolbar=1,resizable=0'); return false;" ><i class="fa fa-google-plus fa"></i><span> google</span></a>
--->
<a class="r" href="http://www.reddit.com/submit?url=https://www.martinholub.com/2024/10/16/RNAi.html" onclick="window.open(this.href, 'mywin',
'left=20,top=20,width=900,height=500,toolbar=1,resizable=0'); return false;"><i class="fa-brands fa-square-reddit"></i><span> reddit</span></a>

<a class="f" href="https://www.facebook.com/sharer/sharer.php?u=https://www.martinholub.com/2024/10/16/RNAi.html" onclick="window.open(this.href, 'mywin',
'left=20,top=20,width=500,height=500,toolbar=1,resizable=0'); return false;" ><i class="fa-brands fa-square-facebook"></i><span> facebook</span></a>

<a class="e" href="mailto:?subject=RNA Interference - Field Recap&amp;body=Check out this site https://www.martinholub.com/2024/10/16/RNAi.html"><i class="fa fa-envelope fa"></i><span> email</span></a>
</div>
<br/>
<hr>


  

<div id="disqus_thread"></div>
    <script type="text/javascript">
        /* * * CONFIGURATION VARIABLES: EDIT BEFORE PASTING INTO YOUR WEBPAGE * * */
        var disqus_shortname = 'martinholub'; // required: replace example with your forum shortname
        /*var disqus_developer = 1; // Comment out when the site is live */
        var disqus_identifier = "/2024/10/16/RNAi.html";

        /* * * DON'T EDIT BELOW THIS LINE * * */
        (function() {
            var dsq = document.createElement('script'); dsq.type = 'text/javascript'; dsq.async = true;
            dsq.src = '//' + disqus_shortname + '.disqus.com/embed.js';
            (document.getElementsByTagName('head')[0] || document.getElementsByTagName('body')[0]).appendChild(dsq);
        })();
    </script>
    <noscript>Please enable JavaScript to view the <a href="http://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
    <a href="http://disqus.com" class="dsq-brlink">comments powered by <span class="logo-disqus">Disqus</span></a>



</div>

      </div>
    </div>

<!--
    <span class="contacticon center">
  <a href="https://www.instagram.com/scimartin/" target="_blank"><i class="fa-brands fa-square-instagram"></i></a>
  <a href="https://www.linkedin.com/in/scimartin" target="_blank"><i class="fa-brands fa-linkedin"></i></a>
  <a href="https://bsky.app/profile/martinholub.com" target="_blank"><i class="fa-brands fa-square-bluesky"></i></a>
  <div class="iconsuperwrapper">
  <a href="https://paragraph.xyz/@scimartin" target="_blank">
  <div class="iconwrapper">
  <svg
   class="icon"
   version="1.0"
   width="36"
   height="36"
   viewBox="0 0 36 36"
   preserveAspectRatio="xMidYMid meet"
   id="svg10"
   sodipodi:docname="paragraph.svg"
   inkscape:version="1.1.1 (3bf5ae0d25, 2021-09-20)"
   xmlns:inkscape="http://www.inkscape.org/namespaces/inkscape"
   xmlns:sodipodi="http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd"
   xmlns="http://www.w3.org/2000/svg"
   xmlns:svg="http://www.w3.org/2000/svg">
  <path
     id="path4"
     d="M 0 0 L 0 12.7273 L 0 25.4546 L 3.73818 25.4546 C 6.04363 25.4546 7.49818 25.4255 7.52727 25.3819 C 7.54909 25.3455 7.61454 25.331 7.66545 25.3528 C 7.82545 25.411 9.96371 25.4254 9.96371 25.3673 C 9.96371 25.3382 10.0073 25.331 10.0582 25.3528 C 10.1164 25.3746 10.2546 25.3964 10.371 25.4037 C 10.5383 25.4182 10.5819 25.4545 10.5746 25.5854 C 10.5746 25.6727 10.5964 25.7455 10.6255 25.7455 C 10.6546 25.7455 10.6546 25.84 10.6183 25.9564 C 10.5892 26.0655 10.5892 26.2036 10.6183 26.2618 C 10.6547 26.3127 10.6547 26.4073 10.6183 26.4728 C 10.5819 26.5382 10.5819 26.6327 10.6109 26.6764 C 10.64 26.7273 10.6473 26.9309 10.6183 27.1273 C 10.5892 27.3237 10.5964 27.5274 10.6255 27.5783 C 10.6546 27.6219 10.6546 27.7164 10.6183 27.7819 C 10.5819 27.8473 10.5819 27.9419 10.6183 28 C 10.6547 28.0582 10.6547 28.1528 10.6183 28.2182 C 10.5819 28.2837 10.5819 28.3782 10.6183 28.4364 C 10.6474 28.4873 10.6474 28.611 10.6183 28.6983 C 10.5747 28.8001 10.5819 28.8873 10.6183 28.9091 C 10.6547 28.9309 10.6547 29.0401 10.6183 29.1637 C 10.5819 29.2873 10.5819 29.3819 10.6183 29.3819 C 10.6547 29.3819 10.6547 29.4764 10.6183 29.6001 C 10.5819 29.7237 10.5819 29.8183 10.6183 29.8183 C 10.6547 29.8183 10.6547 29.9128 10.6183 30.0364 C 10.5819 30.1528 10.5746 30.2546 10.6037 30.2546 C 10.6328 30.2546 10.6546 30.3709 10.6546 30.5091 C 10.6546 30.6473 10.6328 30.7636 10.6037 30.7636 C 10.5746 30.7636 10.5819 30.8582 10.6183 30.9818 C 10.6547 31.0982 10.6547 31.2 10.6183 31.2 C 10.5892 31.2 10.5819 31.2874 10.6109 31.3965 C 10.64 31.5128 10.6401 31.7164 10.6183 31.8691 C 10.5892 32.0146 10.5892 32.1746 10.6255 32.2255 C 10.6546 32.2764 10.6546 32.371 10.6183 32.4364 C 10.5819 32.5019 10.5819 32.5964 10.6183 32.6546 C 10.6547 32.7128 10.6547 32.8073 10.6183 32.8728 C 10.5819 32.9383 10.5819 33.0328 10.6183 33.091 C 10.6474 33.1419 10.6474 33.2655 10.6183 33.3527 C 10.5747 33.4546 10.5819 33.5419 10.6183 33.5637 C 10.6547 33.5855 10.6547 33.6945 10.6183 33.8182 C 10.5819 33.9418 10.5819 34.0364 10.6183 34.0364 C 10.6547 34.0364 10.6547 34.1309 10.6183 34.2545 C 10.5819 34.3782 10.5819 34.4727 10.6183 34.4727 C 10.6547 34.4727 10.6547 34.5673 10.6183 34.6909 C 10.5819 34.8073 10.5746 34.9091 10.6037 34.9091 C 10.6619 34.9091 10.6546 35.4037 10.5965 35.4619 C 10.5747 35.4837 10.582 35.5782 10.6183 35.6727 C 10.6547 35.7673 10.6619 35.8618 10.6401 35.8837 C 10.611 35.9055 16.3128 35.9273 23.2946 35.9273 L 36 35.9273 L 36 22.5455 L 36 9.16364 L 34.7273 9.16364 L 33.4546 9.16364 L 33.4546 21.2873 L 33.4546 33.4183 L 28.5673 33.3964 C 25.8764 33.3891 22.9382 33.3819 22.0364 33.3892 C 21.1345 33.3892 20.3491 33.3964 20.2909 33.3964 C 20.2327 33.3891 18.6327 33.3892 16.7491 33.3892 L 13.3091 33.3818 L 13.3091 29.3819 L 13.3091 25.3746 L 13.5491 25.3818 C 13.6727 25.3818 13.9492 25.3818 14.1601 25.3746 C 14.371 25.3746 14.5746 25.3891 14.6109 25.4109 C 14.6473 25.44 14.6982 25.4255 14.7273 25.3819 C 14.7564 25.3382 14.8074 25.3237 14.8437 25.3528 C 14.9092 25.3891 17.5564 25.4037 18.1091 25.36 C 18.2473 25.3527 18.4364 25.3673 18.5237 25.3964 C 18.611 25.4255 18.7055 25.4182 18.7273 25.3746 C 18.7564 25.3382 18.8073 25.3236 18.8436 25.3527 C 18.8873 25.3745 19.091 25.3963 19.2946 25.3891 C 19.5055 25.3818 19.7455 25.3819 19.8401 25.3819 C 20.1746 25.3819 21.4255 25.1637 21.9273 25.0183 C 22.4364 24.8655 22.56 24.8364 22.7637 24.7855 C 22.8219 24.7782 22.8873 24.7491 22.9091 24.7273 C 22.9309 24.7055 23.2073 24.56 23.5201 24.4073 C 24.1382 24.1164 24.7782 23.7019 25.1127 23.3891 C 25.2218 23.2873 25.3382 23.2001 25.3673 23.1928 C 25.4545 23.1855 26.2037 22.2619 26.5018 21.7964 C 26.8146 21.3164 27.3382 20.0655 27.3455 19.811 C 27.3455 19.731 27.3673 19.6364 27.3964 19.6073 C 27.4255 19.5782 27.4546 19.4327 27.4618 19.28 C 27.4618 19.1273 27.491 18.9601 27.5273 18.9092 C 27.6437 18.7201 27.5928 16.371 27.4546 15.7455 C 27.3891 15.4255 27.3237 15.1127 27.3092 15.0545 C 27.2946 14.96 27.2073 14.7127 27.0764 14.4 C 27.0546 14.3418 27.0255 14.2546 27.0255 14.2182 C 27.0036 14.0582 26.5382 13.2437 26.2255 12.8292 C 25.2219 11.4837 23.3019 10.2764 21.6364 9.92003 C 20.3346 9.64366 20.3564 9.65093 15.4473 9.62184 L 10.6327 9.59275 L 10.6037 9.81093 C 10.5818 9.93457 10.5964 10.0364 10.6255 10.0364 C 10.6546 10.0364 10.6546 10.1309 10.6183 10.2545 C 10.5819 10.3782 10.5819 10.4727 10.6183 10.4727 C 10.6547 10.4727 10.6547 10.5673 10.6183 10.6909 C 10.5819 10.8145 10.5819 10.9091 10.6183 10.9091 C 10.6547 10.9091 10.6547 11.0037 10.6183 11.12 C 10.5892 11.2291 10.5892 11.3673 10.6183 11.4255 C 10.6547 11.4764 10.6547 11.5709 10.6183 11.6364 C 10.5819 11.7019 10.5819 11.7964 10.6183 11.8546 C 10.6547 11.9128 10.6547 12.0073 10.6183 12.0728 C 10.5819 12.1382 10.5819 12.2328 10.6183 12.2909 C 10.6547 12.3491 10.6547 12.4436 10.6183 12.5164 C 10.5819 12.5818 10.5674 12.6546 10.5965 12.6764 C 10.6474 12.7346 10.6546 13.4473 10.5965 13.4982 C 10.5746 13.52 10.5892 13.6364 10.6183 13.7528 C 10.6547 13.8692 10.6547 13.9782 10.6183 14.0001 C 10.5892 14.0219 10.5892 14.1455 10.6183 14.2837 C 10.6474 14.4218 10.6474 14.5745 10.6183 14.6182 C 10.5892 14.6691 10.5892 14.8 10.6183 14.9164 C 10.6547 15.0255 10.6546 15.1345 10.6328 15.1636 C 10.5746 15.2145 10.5965 15.9055 10.6546 16 C 10.6765 16.0437 10.6692 16.0728 10.6256 16.0728 C 10.5819 16.0728 10.5819 16.1528 10.6184 16.291 C 10.6547 16.4146 10.6547 16.5092 10.6184 16.5092 C 10.582 16.5092 10.582 16.6037 10.6184 16.7273 C 10.6547 16.851 10.6547 16.9455 10.6184 16.9455 C 10.582 16.9455 10.582 17.0401 10.6184 17.1637 C 10.6547 17.2873 10.6547 17.3819 10.6184 17.3819 C 10.582 17.3819 10.582 17.4764 10.6184 17.6001 C 10.6547 17.7237 10.6547 17.8182 10.6184 17.8182 C 10.582 17.8182 10.582 17.9128 10.6184 18.0364 C 10.6547 18.1601 10.6547 18.2546 10.6184 18.2546 C 10.582 18.2546 10.582 18.3492 10.6184 18.4728 C 10.6547 18.5964 10.6547 18.691 10.6184 18.691 C 10.582 18.691 10.582 18.7855 10.6184 18.9092 C 10.6547 19.0328 10.6547 19.1273 10.6184 19.1273 C 10.582 19.1273 10.582 19.2219 10.6184 19.3455 C 10.6547 19.4692 10.6547 19.5637 10.6184 19.5637 C 10.582 19.5637 10.5675 19.6073 10.5893 19.6654 C 10.6547 19.84 10.6619 20.24 10.6038 20.4146 C 10.531 20.64 10.6983 20.7419 11.142 20.7346 C 12.0438 20.7128 12.2184 20.72 12.2838 20.7563 C 12.3202 20.7854 12.3711 20.771 12.3929 20.7346 C 12.422 20.6983 12.5238 20.6909 12.6256 20.72 C 12.7347 20.7491 12.931 20.7564 13.0619 20.7419 L 13.3092 20.7128 L 13.2947 16.3855 L 13.2729 12.0582 L 16.6547 12.0946 C 19.9492 12.131 20.5965 12.1745 20.9311 12.3854 C 20.9747 12.4218 21.0183 12.4291 21.0183 12.4073 C 21.0183 12.3346 21.8474 12.6619 22.2474 12.8873 C 23.5492 13.6146 24.2984 14.5819 24.662 16 C 24.8656 16.7782 24.8583 18.2909 24.6546 19.0837 C 24.4582 19.8618 24.0583 20.6546 23.6292 21.1055 C 23.4328 21.3164 23.2729 21.5127 23.2729 21.5418 C 23.2729 21.5709 23.2292 21.6 23.1783 21.6 C 23.1273 21.6 23.0182 21.6582 22.9382 21.7309 C 22.8 21.8473 22.7055 21.9055 22.2255 22.1745 C 21.8764 22.3709 21.1855 22.6182 20.5091 22.7855 C 19.9055 22.931 19.7165 22.9382 11.2219 22.96 L 2.54558 22.9891 L 2.54558 12.7346 L 2.54558 2.47276 L 14.6547 2.47276 L 26.7638 2.47276 L 26.7638 1.23643 L 26.7638 0 L 13.3819 0 Z M 29.3819 0 L 29.3819 1.23643 L 29.3819 2.47276 L 31.4182 2.47276 L 33.4546 2.47276 L 33.4546 4.50916 L 33.4546 6.54545 L 34.7273 6.54545 L 36 6.54545 L 36 3.27273 L 36 0 L 32.6909 0 Z" />
  </svg>
  </div>
  </a>
  </div>
  <br>
  <a href="mailto:scimartin=proton+me"><i class="fa fa-envelope-square"></i></a>
  <a href="https://orcid.org/0000-0002-8365-0927" target="_blank"><i class="ai ai-orcid"></i></a>
  <a href="https://github.com/martinholub" target="_blank"><i class="fa-brands fa-square-github"></i></a>
  <a href="/feed.xml" target="_blank"><i class="fa fa-rss-square"></i></a>
</span>


<div class="col three caption">
	&#169; Martin Holub, 2025
</div>
-->
  <script id="dsq-count-scr" src="//martinholub.disqus.com/count.js" async></script>
  <script src="/css/lightbox.js"></script>

  </body>
    <span class="contacticon center">
  <a href="https://www.instagram.com/scimartin/" target="_blank"><i class="fa-brands fa-square-instagram"></i></a>
  <a href="https://www.linkedin.com/in/scimartin" target="_blank"><i class="fa-brands fa-linkedin"></i></a>
  <a href="https://bsky.app/profile/martinholub.com" target="_blank"><i class="fa-brands fa-square-bluesky"></i></a>
  <div class="iconsuperwrapper">
  <a href="https://paragraph.xyz/@scimartin" target="_blank">
  <div class="iconwrapper">
  <svg
   class="icon"
   version="1.0"
   width="36"
   height="36"
   viewBox="0 0 36 36"
   preserveAspectRatio="xMidYMid meet"
   id="svg10"
   sodipodi:docname="paragraph.svg"
   inkscape:version="1.1.1 (3bf5ae0d25, 2021-09-20)"
   xmlns:inkscape="http://www.inkscape.org/namespaces/inkscape"
   xmlns:sodipodi="http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd"
   xmlns="http://www.w3.org/2000/svg"
   xmlns:svg="http://www.w3.org/2000/svg">
  <path
     id="path4"
     d="M 0 0 L 0 12.7273 L 0 25.4546 L 3.73818 25.4546 C 6.04363 25.4546 7.49818 25.4255 7.52727 25.3819 C 7.54909 25.3455 7.61454 25.331 7.66545 25.3528 C 7.82545 25.411 9.96371 25.4254 9.96371 25.3673 C 9.96371 25.3382 10.0073 25.331 10.0582 25.3528 C 10.1164 25.3746 10.2546 25.3964 10.371 25.4037 C 10.5383 25.4182 10.5819 25.4545 10.5746 25.5854 C 10.5746 25.6727 10.5964 25.7455 10.6255 25.7455 C 10.6546 25.7455 10.6546 25.84 10.6183 25.9564 C 10.5892 26.0655 10.5892 26.2036 10.6183 26.2618 C 10.6547 26.3127 10.6547 26.4073 10.6183 26.4728 C 10.5819 26.5382 10.5819 26.6327 10.6109 26.6764 C 10.64 26.7273 10.6473 26.9309 10.6183 27.1273 C 10.5892 27.3237 10.5964 27.5274 10.6255 27.5783 C 10.6546 27.6219 10.6546 27.7164 10.6183 27.7819 C 10.5819 27.8473 10.5819 27.9419 10.6183 28 C 10.6547 28.0582 10.6547 28.1528 10.6183 28.2182 C 10.5819 28.2837 10.5819 28.3782 10.6183 28.4364 C 10.6474 28.4873 10.6474 28.611 10.6183 28.6983 C 10.5747 28.8001 10.5819 28.8873 10.6183 28.9091 C 10.6547 28.9309 10.6547 29.0401 10.6183 29.1637 C 10.5819 29.2873 10.5819 29.3819 10.6183 29.3819 C 10.6547 29.3819 10.6547 29.4764 10.6183 29.6001 C 10.5819 29.7237 10.5819 29.8183 10.6183 29.8183 C 10.6547 29.8183 10.6547 29.9128 10.6183 30.0364 C 10.5819 30.1528 10.5746 30.2546 10.6037 30.2546 C 10.6328 30.2546 10.6546 30.3709 10.6546 30.5091 C 10.6546 30.6473 10.6328 30.7636 10.6037 30.7636 C 10.5746 30.7636 10.5819 30.8582 10.6183 30.9818 C 10.6547 31.0982 10.6547 31.2 10.6183 31.2 C 10.5892 31.2 10.5819 31.2874 10.6109 31.3965 C 10.64 31.5128 10.6401 31.7164 10.6183 31.8691 C 10.5892 32.0146 10.5892 32.1746 10.6255 32.2255 C 10.6546 32.2764 10.6546 32.371 10.6183 32.4364 C 10.5819 32.5019 10.5819 32.5964 10.6183 32.6546 C 10.6547 32.7128 10.6547 32.8073 10.6183 32.8728 C 10.5819 32.9383 10.5819 33.0328 10.6183 33.091 C 10.6474 33.1419 10.6474 33.2655 10.6183 33.3527 C 10.5747 33.4546 10.5819 33.5419 10.6183 33.5637 C 10.6547 33.5855 10.6547 33.6945 10.6183 33.8182 C 10.5819 33.9418 10.5819 34.0364 10.6183 34.0364 C 10.6547 34.0364 10.6547 34.1309 10.6183 34.2545 C 10.5819 34.3782 10.5819 34.4727 10.6183 34.4727 C 10.6547 34.4727 10.6547 34.5673 10.6183 34.6909 C 10.5819 34.8073 10.5746 34.9091 10.6037 34.9091 C 10.6619 34.9091 10.6546 35.4037 10.5965 35.4619 C 10.5747 35.4837 10.582 35.5782 10.6183 35.6727 C 10.6547 35.7673 10.6619 35.8618 10.6401 35.8837 C 10.611 35.9055 16.3128 35.9273 23.2946 35.9273 L 36 35.9273 L 36 22.5455 L 36 9.16364 L 34.7273 9.16364 L 33.4546 9.16364 L 33.4546 21.2873 L 33.4546 33.4183 L 28.5673 33.3964 C 25.8764 33.3891 22.9382 33.3819 22.0364 33.3892 C 21.1345 33.3892 20.3491 33.3964 20.2909 33.3964 C 20.2327 33.3891 18.6327 33.3892 16.7491 33.3892 L 13.3091 33.3818 L 13.3091 29.3819 L 13.3091 25.3746 L 13.5491 25.3818 C 13.6727 25.3818 13.9492 25.3818 14.1601 25.3746 C 14.371 25.3746 14.5746 25.3891 14.6109 25.4109 C 14.6473 25.44 14.6982 25.4255 14.7273 25.3819 C 14.7564 25.3382 14.8074 25.3237 14.8437 25.3528 C 14.9092 25.3891 17.5564 25.4037 18.1091 25.36 C 18.2473 25.3527 18.4364 25.3673 18.5237 25.3964 C 18.611 25.4255 18.7055 25.4182 18.7273 25.3746 C 18.7564 25.3382 18.8073 25.3236 18.8436 25.3527 C 18.8873 25.3745 19.091 25.3963 19.2946 25.3891 C 19.5055 25.3818 19.7455 25.3819 19.8401 25.3819 C 20.1746 25.3819 21.4255 25.1637 21.9273 25.0183 C 22.4364 24.8655 22.56 24.8364 22.7637 24.7855 C 22.8219 24.7782 22.8873 24.7491 22.9091 24.7273 C 22.9309 24.7055 23.2073 24.56 23.5201 24.4073 C 24.1382 24.1164 24.7782 23.7019 25.1127 23.3891 C 25.2218 23.2873 25.3382 23.2001 25.3673 23.1928 C 25.4545 23.1855 26.2037 22.2619 26.5018 21.7964 C 26.8146 21.3164 27.3382 20.0655 27.3455 19.811 C 27.3455 19.731 27.3673 19.6364 27.3964 19.6073 C 27.4255 19.5782 27.4546 19.4327 27.4618 19.28 C 27.4618 19.1273 27.491 18.9601 27.5273 18.9092 C 27.6437 18.7201 27.5928 16.371 27.4546 15.7455 C 27.3891 15.4255 27.3237 15.1127 27.3092 15.0545 C 27.2946 14.96 27.2073 14.7127 27.0764 14.4 C 27.0546 14.3418 27.0255 14.2546 27.0255 14.2182 C 27.0036 14.0582 26.5382 13.2437 26.2255 12.8292 C 25.2219 11.4837 23.3019 10.2764 21.6364 9.92003 C 20.3346 9.64366 20.3564 9.65093 15.4473 9.62184 L 10.6327 9.59275 L 10.6037 9.81093 C 10.5818 9.93457 10.5964 10.0364 10.6255 10.0364 C 10.6546 10.0364 10.6546 10.1309 10.6183 10.2545 C 10.5819 10.3782 10.5819 10.4727 10.6183 10.4727 C 10.6547 10.4727 10.6547 10.5673 10.6183 10.6909 C 10.5819 10.8145 10.5819 10.9091 10.6183 10.9091 C 10.6547 10.9091 10.6547 11.0037 10.6183 11.12 C 10.5892 11.2291 10.5892 11.3673 10.6183 11.4255 C 10.6547 11.4764 10.6547 11.5709 10.6183 11.6364 C 10.5819 11.7019 10.5819 11.7964 10.6183 11.8546 C 10.6547 11.9128 10.6547 12.0073 10.6183 12.0728 C 10.5819 12.1382 10.5819 12.2328 10.6183 12.2909 C 10.6547 12.3491 10.6547 12.4436 10.6183 12.5164 C 10.5819 12.5818 10.5674 12.6546 10.5965 12.6764 C 10.6474 12.7346 10.6546 13.4473 10.5965 13.4982 C 10.5746 13.52 10.5892 13.6364 10.6183 13.7528 C 10.6547 13.8692 10.6547 13.9782 10.6183 14.0001 C 10.5892 14.0219 10.5892 14.1455 10.6183 14.2837 C 10.6474 14.4218 10.6474 14.5745 10.6183 14.6182 C 10.5892 14.6691 10.5892 14.8 10.6183 14.9164 C 10.6547 15.0255 10.6546 15.1345 10.6328 15.1636 C 10.5746 15.2145 10.5965 15.9055 10.6546 16 C 10.6765 16.0437 10.6692 16.0728 10.6256 16.0728 C 10.5819 16.0728 10.5819 16.1528 10.6184 16.291 C 10.6547 16.4146 10.6547 16.5092 10.6184 16.5092 C 10.582 16.5092 10.582 16.6037 10.6184 16.7273 C 10.6547 16.851 10.6547 16.9455 10.6184 16.9455 C 10.582 16.9455 10.582 17.0401 10.6184 17.1637 C 10.6547 17.2873 10.6547 17.3819 10.6184 17.3819 C 10.582 17.3819 10.582 17.4764 10.6184 17.6001 C 10.6547 17.7237 10.6547 17.8182 10.6184 17.8182 C 10.582 17.8182 10.582 17.9128 10.6184 18.0364 C 10.6547 18.1601 10.6547 18.2546 10.6184 18.2546 C 10.582 18.2546 10.582 18.3492 10.6184 18.4728 C 10.6547 18.5964 10.6547 18.691 10.6184 18.691 C 10.582 18.691 10.582 18.7855 10.6184 18.9092 C 10.6547 19.0328 10.6547 19.1273 10.6184 19.1273 C 10.582 19.1273 10.582 19.2219 10.6184 19.3455 C 10.6547 19.4692 10.6547 19.5637 10.6184 19.5637 C 10.582 19.5637 10.5675 19.6073 10.5893 19.6654 C 10.6547 19.84 10.6619 20.24 10.6038 20.4146 C 10.531 20.64 10.6983 20.7419 11.142 20.7346 C 12.0438 20.7128 12.2184 20.72 12.2838 20.7563 C 12.3202 20.7854 12.3711 20.771 12.3929 20.7346 C 12.422 20.6983 12.5238 20.6909 12.6256 20.72 C 12.7347 20.7491 12.931 20.7564 13.0619 20.7419 L 13.3092 20.7128 L 13.2947 16.3855 L 13.2729 12.0582 L 16.6547 12.0946 C 19.9492 12.131 20.5965 12.1745 20.9311 12.3854 C 20.9747 12.4218 21.0183 12.4291 21.0183 12.4073 C 21.0183 12.3346 21.8474 12.6619 22.2474 12.8873 C 23.5492 13.6146 24.2984 14.5819 24.662 16 C 24.8656 16.7782 24.8583 18.2909 24.6546 19.0837 C 24.4582 19.8618 24.0583 20.6546 23.6292 21.1055 C 23.4328 21.3164 23.2729 21.5127 23.2729 21.5418 C 23.2729 21.5709 23.2292 21.6 23.1783 21.6 C 23.1273 21.6 23.0182 21.6582 22.9382 21.7309 C 22.8 21.8473 22.7055 21.9055 22.2255 22.1745 C 21.8764 22.3709 21.1855 22.6182 20.5091 22.7855 C 19.9055 22.931 19.7165 22.9382 11.2219 22.96 L 2.54558 22.9891 L 2.54558 12.7346 L 2.54558 2.47276 L 14.6547 2.47276 L 26.7638 2.47276 L 26.7638 1.23643 L 26.7638 0 L 13.3819 0 Z M 29.3819 0 L 29.3819 1.23643 L 29.3819 2.47276 L 31.4182 2.47276 L 33.4546 2.47276 L 33.4546 4.50916 L 33.4546 6.54545 L 34.7273 6.54545 L 36 6.54545 L 36 3.27273 L 36 0 L 32.6909 0 Z" />
  </svg>
  </div>
  </a>
  </div>
  <br>
  <a href="mailto:scimartin=proton+me"><i class="fa fa-envelope-square"></i></a>
  <a href="https://orcid.org/0000-0002-8365-0927" target="_blank"><i class="ai ai-orcid"></i></a>
  <a href="https://github.com/martinholub" target="_blank"><i class="fa-brands fa-square-github"></i></a>
  <a href="/feed.xml" target="_blank"><i class="fa fa-rss-square"></i></a>
</span>


<div class="col three caption">
	&#169; Martin Holub, 2025
</div>

</html>
